Remegen (09995) rose more than 3%, as of press time, up 3.25%, reporting HKD 14.62, with a turnover of 8.3875 million HKD.
According to the Wisdom Financial mobile app, Remegen (09995) rose more than 3% and, as of press time, was up 3.25%, reporting HKD 14.62, with a turnover of 8.3875 million HKD.
On the news front, Remegen recently announced that its independently developed BLyS/APRIL dual-target fusion protein innovative drug RC18 (trade name: TaiLove) for the treatment of systemic myasthenia gravis (gMG) global Phase III clinical trial has successfully achieved the first patient enrollment in the United States. At the same time, the company also stated that the domestic Phase III clinical trial of gMG indications has been basically completed and results will be available soon.